CHDArrhythmiasDiabetesLipidologyHeart FailureHypertensionStrokeThrombosis
Log in
Username
Password
Bookmark this site|Register Me|Forgotten Password
Welcome to InCirculation.net
InCirculation.net is a professional cardiovascular resource intended for a global audience of specialists, generalists, researchers, and other healthcare professionals
Would you like to know what else InCirculation.net has to offer? Take the tour of InCirculation.net
Click here to register
You can review the latest news articles without logging in, but registration allows you to access all the information and have the choice of receiving an e-mail informing you of the latest updates to the site.

AHA 2008 Congress Coverage

InCirculation.net reported from the AHA Scientific Sessions 2008 in New Orleans. Our comprehensive coverage included news and exclusive interviews on JUPITER, I-PRESERVE, TIMACS, HF-ACTION and all the other major Late-Breakers. Our in-depth Congress Reports round up our coverage, keeping you abreast of all the talking points from the meeting.

Audio Highlights

Click to listen or right-click to save as a podcast

SEAS Trial
JUPITER trial In this exclusive interview with InCirculation.net editorial board member Roger Hall, Andrew Tonkin discusses the implications of the JUPITER trial, a landmark study demonstrating that rosuvastatin treatment significantly reduces the risk of cardiovascular disease morbidity and mortality in apparently healthy individuals.

TIMACS
TIMACSDeepak Bhatt reviews the TIMACS trial, a comparison of early and late interventional management in ACS patients.
HF-ACTION
HF-ACTIONIgnore the purists, HF-ACTION findings on exercise in heart failure patients are “compelling” says Philip Poole-Wilson to InCirculation.net interviewer John McMurray.

ATLAS ACS-TIMI 46
ATLAS ACS-TIMI 46Freek Verheugt reviews the promising results of ATLAS, a phase II trial evaluating the safety of rivaroxiban treatment in ACS patients.
SEARCH
SEARCHDespite the spin, SEARCH was a “double-null outcome”, says Peter Wilson in this discussion with Sidney Goldstein.

I-PRESERVE
I-PRESERVEJohn Cleland gives his views on I-PRESERVE, a study of ARB treatment in a type of heart failure mostly affecting women and the elderly.
JPAD
JPADMarian Limacher addresses the results and wider implications of the JPAD trial, which assessed the use of aspirin to prevent atherosclerosis in diabetic patients.

What's New

28 October 2008

Editorial: BEAUTIfUL: Ivabradine in heart failure
By: Sidney Goldstein
The importance of the bradycardic effect of beta blockade in heart failure is now being tested with the development of drugs such as ivabradine that can slow the heart by inhibiting the If current in the sinoatrial node. Sidney Goldstein discusses the results of the BEAUTIfUL trial, which provides insight into the potential of these drugs in the treatment of patients with heart failure.


12 September 2008

Editorial: Chest compression-only for cardiac arrest?
By: Douglas Chamberlain
The long-held norm for the resuscitation of cardiac arrest victims has involved both chest compressions and mouth-to-mouth ventilation. However, recent evidence has questioned whether compression-only resuscitation should be taught. Douglas Chamberlain, Honorary Professor of Resuscitation Medicine, Cardiff University, UK, reviews the arguments relevant to this controversy.


28 August 2008

Editorial: Antihypertensive treatment: Is anybody old enough to make treatment useless?
By: Alberto Zanchetti
The results of the HYVET trial on the benefits of blood pressure lowering in the very old hypertensive (aged 80 years or older) have recently been published. Alberto Zanchetti provides in-depth discussion of the importance of this trial for the management of hypertension.


All rights reserved. This website is intended for an international audience. Privacy PolicyLegal NoticeTerms and Conditions
Site features